Blunted Cytopenias and Weight Loss: New Correlates of Virologic Null Response to Re-treatment of Chronic Hepatitis C

Clinical Gastroenterology and Hepatology

Volumn 6, Issue 2, 2008, Pages 234-241

  Lindsay, Karen L ^a   Morishima, Chihiro ^b   Wright, Elizabeth C ^c   Dienstag, Jules L ^d   Shiffman, Mitchell L ^e   Everson, Gregory T ^f   Lok, Anna S F ^g   Bonkovsky, Herbert L ^h   Lee, William M ⁱ   Morgan, Timothy R ^j,k   Ghany, Marc G ^l  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NEW ENGLAND RESEARCH INSTITUTES   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^h UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^l NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; AFRICAN AMERICAN; ARTICLE; BLUNTED CYTOPENIA; BODY WEIGHT; CONTROLLED STUDY; CYTOPENIA; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; LEUKOCYTE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; RACE DIFFERENCE; RETREATMENT; THROMBOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; VIROLOGY; WEIGHT REDUCTION;

ETHNIC GROUPS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LEUKOPENIA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRAL LOAD; WEIGHT LOSS;

EID: 38749112245     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2007.11.020     Document Type: Article

References (37)

1. Manns M.P., McHutchinson J.G., Gordon S.C., et al. Peginterferon-alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358 (2001) 958-965
2. Fried M.W., Shiffman M.L., Reddy K.R., et al. Combination of peginterferon alfa-2a (40 kd) plus ribavirin in patients with chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
3. Di Bisceglie A.M., and Hoofnagle J.H. Optimal therapy of hepatitis C. Hepatology 36 (2002) S121-S127
4. National Institutes of Health Consensus Development Conference Panel. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002. Hepatology 36 (2002) S3-S20
5. Hadziyannis S.J., Sette J., Morgan T.R., et al., PEGASYS International Study Group. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 140 (2004) 346-355
6. Zeuzem S., Diago M., Gane E., et al., PEGASYS Study NR16071 Investigator Group. Peginterferon alfa-2a (40 Kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 127 (2004) 1724-1732
7. Lindsay K.L. Introduction to therapy of hepatitis C. Hepatology 36 (2002) S114-S120
8. McHutchison J.G., Manns M., Patel K., et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123 (2002) 1061-1069
9. Perelson A.S., Herrmann E., Micol F., et al. New kinetic models for the hepatitis C virus. Hepatology 42 (2005) 749-754
10. Neumann A.U., Lam N.P., Dahari H., et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282 (1998) 103-107
11. Herrmann E., Lee J.H., Marinos G., et al. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37 (2003) 1351-1358
12. Layden-Almer J.E., Ribeiro R.M., Wiley T., et al. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 37 (2003) 1343-1350
13. Lee W.L., Dienstag J.L., Lindsay K.L., et al., HALT-C Trial Group. Evolution of the HALT-C trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 25 (2004) 472-492
14. Shiffman M.L., Di Bisceglie A.M., Lindsay K.L., et al. Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 126 (2004) 1015-1023
15. Nguyen T.T., Sedghi-Vaziri A., Wilkes L.B., et al. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat 3 (1996) 75-78
16. Pontisso P., Bellati G., Brunetto M., et al. Hepatitis C virus RNA profiles in chronically infected individuals: do they relate to disease activity?. Hepatology 29 (1999) 585-589
17. Yeo A.E.T., Ghany M., Conry-Cantilena C., et al. Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. J Viral Hepat 8 (2001) 256-263
18. Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
19. Lee S.C., Antony A., Lee N., et al. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol 38 (2000) 4171-4179
20. Cobas Amplicor™ Hepatitis C Virus Test, Version 2.0. Package insert (2001), Roche Molecular Systems, Branchburg, NJ
21. Morishima C., Morgan T.R., Everhart J.E., et al., HALT-C Trial Group. HCV RNA detection by TMA during the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) trial. Hepatology 44 (2006) 360-367
22. Stuyver L., Wyseur A., Van Arnhem W., et al. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 34 (1996) 2259-2266
23. Hayashi M., Floyd Jr. J.C., and Pek S. Insulin, proinsulin, glucagon and gastrin in pancreatic tumors and in plasma of patients with organic hyperinsulinism. J Clin Endocrinol Metab 44 (1977) 681-694
24. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20 (1997) 1183-1197
25. Matthews D.R., Hosker J.P., and Rudenski A.S. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
26. Berg T., Von Wagner M., Nasser S., et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 to 72 weeks of peginterferon alfa-2a plus ribavirin. Gastroenterology 130 (2006) 1086-1097
27. Pearlman B.L. Chronic hepatitis C therapy: changing the rules of duration. Clin Gastroenterol Hepatol 4 (2006) 963-971
28. Sherman K.E., Fleischer R., Laessig K., et al. Development of novel agents for the treatment of chronic hepatitis C infection: summary of the FDA antiviral products advisory committee recommendations. Hepatology 46 (2007) 2014-2020
29. Di Bisceglie A.M., Fax X., Chambers T., et al. Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder. J Med Virol 78 (2006) 446-451
30. Feld J.J., and Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436 (2005) 967-972
31. Reddy K.R., Hoofnagle J.H., Tong M.J., et al., Consensus Interferon Study Group. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 30 (1999) 787-793
32. Jeffers L.J., Cassidy W., Howell C.D., et al. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 39 (2004) 1702-1708
33. Muir A.J., Bornstein J.D., Killenberg P.G., and Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 350 (2004) 2265-2271
34. Bamshad M. Genetic influences on health. Does race matter?. JAMA 294 (2005) 937-946
35. Conjeevaram H.S., Fried M.W., Jeffers L.J., et al., Virahep-C Study Group. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131 (2006) 470-477
36. Taylor M.W., Tsukahara T., Brodsky L., et al., ViraHep-C Study Group. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol 81 (2007) 3391-3401
37. Gale M., and Foy E.M. Evasion of intracellular host defence by hepatitis C virus. Nature 436 (2005) 939-945